We also showed that the expression of FASN is regulated by SREBP1/SPREBP2 and that the combination of FASN and SREBP inhibitors enhanced the effects on both CTCL cell lines and primary SS patient cells. Here, SREBF1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.